SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate earnings, with discussions focusing on potential revenue beats and updated guidance. The community is weighing the possibility of a post-earnings surge against concerns of short-term manipulation, and a few investors are citing potential rate cuts as catalysts for the stock.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending amid mixed sentiment, with some traders citing a potential bottom after a period of decline, while others express concerns about manipulation and the company's long-term prospects. A recent NFL apparel partnership is a key catalyst mentioned, though some question its impact, and overall discussion centers on whether the stock is poised for a rebound or further downside. Community members are actively debating analyst ratings and potential activist involvement.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending as the company recently launched new AI chips aimed at competing with Nvidia and AMD in the data center market, generating significant buzz and a surge in stock price. Community discussions revolve around the potential impact of these chips, revenue projections, and whether Qualcomm can truly challenge the dominance of existing players. Some analysts express skepticism, citing the chips' specifications and disclosed customer base, while others highlight the company's shift towards AI infrastructure.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond ($BBBY) is trending as the company reclaims its original ticker symbol after Overstock's rebranding, sparking discussions of meme stock potential and a possible short squeeze. Community members are debating the impact of blockchain initiatives tied to tZERO and speculating about strategic moves by key figures like Ryan Cohen. Bearish investors cite concerns about dilution and cash burn while bullish investors focus on potential new directions for the company.

Trump For President

Trump Crypto is trending amid mixed community sentiment, with some users discussing potential pumps and scams while others express political opinions related to Trump. Bullish investors are anticipating gains, while bearish investors are pointing to the coin's performance since launch. The coin seems to be moving in response to triggers related to its namesake figure.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as investors weigh the potential impact of a new web browser from OpenAI, a possible competitor to Google Chrome. Despite the concerns, many community members view the dip as a buying opportunity, emphasizing Google's diverse portfolio and strong position in AI and cloud computing.  Additionally, some analysts have recently raised their price targets for the stock, citing positive advertising and cloud channel checks.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

CLIK is trending due to a significant volume spike and discussions around its potential for a parabolic move. Community members are closely watching for continuation and a possible short squeeze, citing a very low float and insider ownership. Some traders are also pointing to a recent revenue growth update as a potential catalyst.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the following segments: Advanced Technology Solutions (ATS), and Connectivity and Cloud Solutions (CCS). The Advanced Technology Solutions (ATS) segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The Connectivity and Cloud Solutions (CCS) segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica ($CLS) is trending due to positive community sentiment and strong reactions to recent earnings, with many calling the results a "monster" beat. The community is buzzing about the company's potential, with some drawing comparisons to $NVDA and anticipating significant future growth. The stock's performance is also being discussed in the context of the broader tech sector and AI infrastructure.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

NTLA is trending as investors assess the impact of a trial pause due to a patient experiencing liver enzyme elevations, leading to a significant stock drop and analyst price target reductions. The community is debating whether this is an overreaction and a buying opportunity, citing the company's strong cash reserves and continued buy ratings from some analysts. Some traders anticipate a short squeeze, while others express concerns about the long-term implications for NTLA's lead program.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group (UNH) is trending as investors anticipate the company's earnings report, with some expecting a positive surprise due to lowered expectations and potential catalysts like a DOJ decision. The community is actively discussing options strategies, with some bulls hedging their bets, while others express concerns about margin pressures and potential negative impacts. Optimism remains among some, citing Warren Buffett's backing and potential for long-term growth despite near-term challenges.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Conduit Pharmaceuticals Inc. (CDT) tumbled 17% on Wednesday after the company announced that it has entered into a development agreement with privately held animal health company Manoira Corporation.As part of the <a target="_blank" rel="noopener noreferrer nofollow" href="https://s3.amazonaws.com/b2icontent.irpass.cc/2892/rl146071.pdf">agreement</a>, Manoira will evaluate Conduit's clinical-stage candidates AZD1656 and AZD5658 in animal health indications.Manoira will initially focus on the evaluation of AZD1656 in animal Osteoarthritis. Osteoarthritis is a degenerative joint condition in companion animals.The collaboration will help Conduit accelerate its understanding of AZD1656's mechanism of action, safety profile, and potential efficacy across species, while retaining ownership of all data and intellectual property generated for human applications.The partnership, Conduit said, opens potential new revenue streams in the high-growth veterinary market.The parties will determine any future financial benefits and implications upon review of the results of the evaluations and how to proceed as a result of any such findings, Conduit said.Manoira has agreed to fund all the developmental activities of the collaboration, and Conduit has agreed to issue Manoira an up-front consideration of $500,000. Conduit’s consideration will be settled through the issuance of 154,799 shares of common stock at $3.23, or its closing price on Tuesday.On Stocktwits, retail sentiment around CDT stayed unmoved within the ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1264/128;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_04_at_11_58_35_AM_png_7bfe8d0833.webp" alt="CDT's Sentiment Meter and Message Volume as of 12:00 p.m. ET on June 4, 2025 | Source: Stocktwits" width="1264" height="128"><figcaption>CDT's Sentiment Meter and Message Volume as of 12:00 p.m. ET on June 4, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that they bought the stock during the dip.<stembedurl>https://stocktwits.com/BankingBig/message/616778690</stembedurl>Another sees it rising back to over $10.<stembedurl>https://stocktwits.com/LetsgoDudeszi/message/616768852</stembedurl><a href="https://stocktwits.com/symbol/CDT">CDT stock</a> is down by approximately 98% this year and has lost most of its value over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/lucid-inks-deal-with-graphiteone/chkuKwsRbwU">Lucid Inks Deal With Graphite One To Strengthen Local Graphite Supply Chain: Retail Sees Stock Hitting $3 To $5 In Coming Months</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Conduit Pharmaceuticals Enters Development Agreement With Manoira To Test Drugs In Animals: Retail Sees Stock Above $10

Manoira will initially focus on the evaluation of AZD1656 in animal Osteoarthritis.

Equity

Shares of Conduit Pharmaceuticals Inc. (CDT) dropped 5% on Friday morning after the company’s board <a target="_blank" rel="noopener noreferrer nofollow" href="https://s3.amazonaws.com/b2icontent.irpass.cc/2892/rl145666.pdf">approved</a> a 1-for-15 reverse stock split of its common stock.Earlier, shareholders approved the stock split proposal in a meeting on May 5, leaving it upon the board to determine the exact split ratio.The company said the reverse stock split will become effective on May 19 at 5:00 p.m. ET, and the stock will start trading on a reverse stock-split adjusted basis at market open on May 20.On May 19 evening, every 15 shares of the firm’s issued and outstanding common stock will be combined into one share, reducing the number of outstanding shares of common stock to about 755,900.The company said no fractional shares will be issued in connection with the split, and those entitled to a fractional share will instead receive a proportional cash payment.Earlier this month, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://s3.amazonaws.com/sec.irpass.cc/2892/0001641172-25-010405.htm">flagged</a> doubts regarding its ability to continue as a going concern for at least the next 12 months.It said management has determined it does not have sufficient cash and other sources of liquidity to fund its current business plan, adding that it had cash and cash equivalents of only $2.1 million as of the end of the first quarter.On Stocktwits, retail sentiment around Conduit Pharmaceuticals remained unmoved within the ‘bearish’ territory over the past 24 hours while message volume remained at ‘extremely low’ levels.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_16_at_10_29_21_AM_png_0ccaac1374.webp" alt="CDT's Sentiment Meter and Message Volume as of 10:30 a.m. ET on May 16, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>CDT's Sentiment Meter and Message Volume as of 10:30 a.m. ET on May 16, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user, however, expressed skepticism about the stock’s performance.<stembedurl>https://stocktwits.com/rkfrkf/message/614872963</stembedurl>The shares closed at over $1 last in early April.<a href="https://stocktwits.com/symbol/CDT">CDT stock</a> is down 95% this year and has lost nearly all of its value over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/trump-says-tariff-deals-with-other-countries-in-two-three-weeks/chiwIazRbnt">Trump Says Tariff Deals With Other Nations To Be Set Within 2 To 3 Weeks: ‘I Think We’re Going To Be Very Fair’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Conduit Pharma Stock Drops On Reverse Stock Split Announcement: Retail’s Pessimistic

The company said that the reverse stock split will become effective on May 19 at 5:00 p.m. ET, and the stock will start trading on a reverse stock-split adjusted basis at market open on May 20. 

Conduit Pharma Stock Drops On Reverse Stock Split Announcement: Retail’s Pessimistic 

The company said that the reverse stock split will become effective on May 19 at 5:00 p.m. ET, and the stock will start trading on a reverse stock-split adjusted basis at market open on May 20. 


EXCLUSIVE: Penny Stock Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets

Conduit Pharmaceuticals has entered an exclusive licensing agreement with AstraZeneca to develop AZD1656, AZD5658, and AZD5904, targeting autoimmune disorders and idiopathic male infertility. Conduit...

What Happened With Conduit Pharmaceuticals (CDT) Stock Today?

Conduit Pharmaceuticals shares traded higher by over 50% early Tuesday. The company announced it received patent approval for its lead asset targeting autoimmune diseases.
read more...

Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer

Conduit also appoints prominent intellectual property attorney Jeffrey Lindeman as a Consultant Leadership additions underscore Conduit's commitment to strengthening and broadening its intellectual...

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Short Interest Down 39.1% in February

Conduit Pharmaceuticals Inc. (NASDAQ:CDT  Get Free Report) was the recipient of a large decline in short interest in the month of February. As of February 29th, there was short interest...

Conduit Pharmaceuticals opens laboratory space in Cambrige, UK

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe's Leading Life Sciences Hub

SAN DIEGO and LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit") today announced the opening of cutting-edge laboratory...

Private equity firms among Conduit Pharmaceuticals Inc.'s (NASDAQ:CDT) largest shareholders, saw gain in holdings value after stock jumped 18% last week

Key Insights Significant control over Conduit Pharmaceuticals by private equity firms implies that the general public...

Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

SAN DIEGO and LONDON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit"), a multi-asset, clinical-stage life science company delivering an efficient model for...

CDT Equity, Inc. engages in facilitating the development and commercialization of clinical assets. The company was founded by David Joszef Tapolczay and Freda C. Lewis-Hall in October 2021 is headquartered in Naples, FL.

CDT Equity Inc.

Will Alphabet ($GOOGL) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Alphabet Inc Class A

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$3.07
Prev Close	$3.01
Open	$3.06
Dividend Yield	0.00%
50-Day Moving Average	$6.96
Beta	0.72
Avg. Volume	1.51M
PE Ratio	0.00

52-Week High	$2,198.40
52-Week Low	$2.72
Market Capitalization	$1.15M
EPS (Annual)	-$2,463.72
Price to Book	0.26
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

CDT
Conduit Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CDT News

CDTConduit Pharmaceuticals Inc